• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does Vagus Nerve Stimulation Work for Treatment-Resistant Depression?

Does Vagus Nerve Stimulation Work for Treatment-Resistant Depression?

February 1, 2018
Adam Strassberg, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Aaronson ST et al, Am J Psychiatry 2017;174(7):640–648

Treatment-resistant depression (TRD) is typically defined as a major depression that fails to remit after at least 2 trials of 2 different classes of antidepressants. Other than electroconvulsive therapy (ECT), there remain few evidence-based biological treatment options for TRD.

In 2005, the FDA approved vagus nerve stimulation (VNS), where a small stimulator device is surgically implanted in the chest, with three small electrodes wrapped around the vagus nerve. The device was originally approved for use with treatment-refractory epilepsy, although the approval was very controversial due to the poor quality of the data. TCPR was unconvinced that VNS had shown any evidence of being more effective for depression than sham treatment (see TCPR, January 2006). As a condition of approval, the FDA required post-marketing surveillance, and so the Treatment-Resistant Depression Registry was established.

The authors of this study, a 5-year longitudinal observational study conducted at 61 separate U.S. sites, used the registry to follow the clinical course and outcome of 2 large groups of patients diagnosed with TRD. One group received adjunctive VNS, and the other group received treatment as usual (TAU).

The patients could select their treatment—VNS or TAU—and 795 patients were included (495 patients in the VNS arm and 301 in the TAU arm). All patients had previously failed 4 or more treatments, with an average of 8.2 failed treatments. Response was defined as a decrease of > 50% in baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score, and remission was based on a MADRS score ≤ 9.

The adjunctive VNS group had better clinical outcomes than the TAU group, including a significantly higher 5-year cumulative response rate (67.6% compared to 40.9%, p < 0.001), and a significantly higher remission rate (43.3% compared to 25.7%, p < 0.001).

TCPR’s Take

This study suggests that VNS is effective for TRD, but this treatment does not work quickly. Differences did not emerge until 6–9 months after treatment. Further, the study design had many limitations. Patients were not randomly assigned to treatment groups, there was no sham “placebo” comparison, and neither patients nor researchers were blinded to treatment. In addition, the study was funded by Cyberonics, the manufacturer of the device. While commercial funding does not necessarily imply that a study’s results are invalid, it does behoove us to give the results extra scrutiny.

VNS is a complicated surgical procedure requiring a large investment in both time and money. Whether the potential benefits are worth the costs must be weighed individually for each patient. This study does suggest, however, that VNS is a potentially useful treatment for a small group of patients with treatment-refractory depression.
General Psychiatry
KEYWORDS brain_devices research-update
    Adam Strassberg, MD

    Probiotics for Bipolar Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Working With Families, TCPR, February 2018
    Note From the Editor-in-Chief
    Involving Families Enhances Patient Outcomes
    Tips for Effective Family Meetings
    Holding Effective Family Meetings
    Does Vagus Nerve Stimulation Work for Treatment-Resistant Depression?
    Is D-Cycloserine Useful for Panic Disorder Treatment Augmentation?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.